Naphazoline / Pheniramine
Naphazoline / Pheniramine is a combination eye drop used to temporarily relieve itchy, red eyes caused by common allergens such as pollen, ragweed, grass, and animal hair and dander.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 12 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Naphazoline / Pheniramine: Patient Information Guide
A plain-language walkthrough of Naphazoline / Pheniramine — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Naphazoline / Pheniramine eye drops are used to temporarily ease two allergy-related eye symptoms: itching and redness. All supported products treat the same set of allergen triggers:
- Pollen
- Ragweed
- Grass
- Animal hair
- Animal dander
All five products — Naphcon A, Opcon-A, Eye Allergy Relief, Naphazoline HCl And Pheniramine Maleate, and Visine Allergy Eye Relief Multi-Action — are ophthalmic (eye) drops approved for this temporary relief. None of these products is intended to treat the underlying allergy itself.
💊How it's taken▾
These drops are applied directly to the eye(s). Adults and children aged 6 and older may use 1 or 2 drops in the affected eye(s) up to 4 times a day — this applies across all supported products. Children under 6 should not use these drops without a doctor's guidance.
- Remove contact lenses before putting in the drops
- Do not touch the tip of the container to your eye or any other surface
- Replace the cap right after each use
- Do not use more often than directed — overuse can cause increased eye redness
Follow the directions on your product's label or as advised by your pharmacist or prescriber.
🤒Side effects — in detail▾
Most people tolerate these drops well, but a few mild effects can happen:
- A brief tingling or stinging sensation after putting in the drops
- Temporary pupil enlargement, which can cause some light sensitivity
- Increased eye redness if the drops are used too frequently
Stop using the drops and contact your doctor if you have eye pain, notice changes in your vision, or if redness or irritation gets worse or doesn't improve within 72 hours — these could be signs of something that needs medical attention.
⚠️Warnings & precautions▾
- Accidental swallowing is an emergency — especially in infants and young children. It can lead to coma and a dangerous drop in body temperature. Keep these drops out of reach of children and call Poison Control or seek emergency help immediately if ingestion occurs.
- Ask a doctor before using if you have heart disease, high blood pressure, an enlarged prostate gland, or narrow angle glaucoma (a type of increased eye pressure).
- Overuse can make eye redness worse — do not use more often than directed.
- Do not use if the solution has changed color or looks cloudy.
- Your pupils may temporarily enlarge while using these drops, causing mild light sensitivity — this is expected but temporary.
- Do not wear contact lenses while using the drops; remove them first.
🔀What it interacts with▾
The label does not list specific drug or food interactions for these products.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not use if you are sensitive or allergic to any ingredient in the product
- Tell your doctor if you have heart disease before using
- Tell your doctor if you have high blood pressure before using
- Tell your doctor if you have trouble urinating due to an enlarged prostate gland
- Tell your doctor if you have narrow angle glaucoma (increased pressure inside the eye)
- Children under 6 years old should not use these drops without a doctor's approval
- Remove contact lenses before using the drops
- Do not use if the solution has changed color or become cloudy
🚑If you take too much▾
If these drops are accidentally swallowed — particularly by an infant or small child — the effects can be serious, including coma and a marked drop in body temperature. If swallowing occurs, get medical help or contact a Poison Control Center right away. Do not wait for symptoms to appear.
📦How to store it▾
Store at room temperature 20 degrees - 25 degrees C ( 68 degrees - 77 degrees F). Protect from light.
📄 Written from Naphazoline / Pheniramine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Naphazoline / Pheniramine — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly does this product do for my eyes? ▾
How often can I use these drops? ▾
Can I wear my contact lenses while using these drops? ▾
My eyes look a little different after using the drops — is that normal? ▾
Are these drops safe if I have other health conditions like high blood pressure or glaucoma? ▾
What should I do if my child accidentally swallows some of these drops? ▾
Is Naphazoline / Pheniramine available over the counter? ▾
When was Naphazoline / Pheniramine first available? ▾
Who makes Naphazoline / Pheniramine? ▾
💬 Answers drafted from Naphazoline / Pheniramine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Naphazoline / Pheniramine comes
Naphazoline / Pheniramine is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Eye drops
How this form is used
- Naphcon A temporarily relieves redness and itching due to ragweed pollen, grass, animal dander, and animal hair
- Opcon-A temporarily relieves itching and redness caused by pollen, ragweed, grass, animal hair, and dander
- Eye Allergy Relief temporarily relieves itching and redness caused by pollen, ragweed, grass, animal hair, and dander
- Visine Allergy Eye Relief Multi-Action temporarily relieves itchy, red eyes due to pollen, ragweed, grass, animal hair, and dander
- Naphcon A: adults and children 6 years and over may put 1 or 2 drops in the affected eye(s) up to 4 times daily; children under 6 should ask a doctor
- Opcon-A and Eye Allergy Relief: adults and children 6 years and older may instill 1 or 2 drops in the affected eye(s) up to 4 times daily; children under 6 should ask a doctor
- Visine Allergy Eye Relief Multi-Action: adults and children 6 years and over may put 1 or 2 drops in the affected eye(s) up to 4 times a day; children under 6 should consult a doctor
- Remove contact lenses before using; do not touch the dropper tip to any surface; replace the cap after each use
📊 Naphazoline / Pheniramine across the U.S. market
How Naphazoline / Pheniramine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Naphazoline / Pheniramine is used
A general measure of how commonly Naphazoline / Pheniramine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Naphazoline / Pheniramine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Naphazoline / Pheniramine prescribed? Of the 1,597 medications we measure, Naphazoline / Pheniramine ranks #1,169 by Medicaid prescriptions — more than 27% of them.
Utilization by Naphazoline / Pheniramine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
naphazoline hydrochloride 0.25 MG/ML / pheniramine maleate 3 MG/ML Ophthalmic Solution
Summed across the 1 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1043658
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Naphazoline / Pheniramine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 14 listed Naphazoline / Pheniramine NDCs with Medicaid activity.
🔍 Compare Naphazoline / Pheniramine products
A representative set of FDA-listed product records for Naphazoline / Pheniramine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Eye drops | ||||
| NAPHAZOLINE HYDROCHLORIDE 0.25 mg/mL; PHENIRAMINE MALEATE 3 mg/mL | Ophthalmic | A-S Medication Solutions | NDA | View NDC → |
| 0.25; 3 mg/mL; mg/mL | Ophthalmic | A-S Medication Solutions | NDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.25 mg/mL; PHENIRAMINE MALEATE 3 mg/mL | Ophthalmic | Alcon Laboratories, Inc. | NDA | View NDC → |
| 0.25; 3 mg/mL; mg/mL | Ophthalmic | Alcon Laboratories, Inc. × 2 listings | NDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.27 mg/mL; PHENIRAMINE MALEATE 3.15 mg/mL | Ophthalmic | Altaire Pharmaceuticals Inc. | ANDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.2675 mg/mL; PHENIRAMINE MALEATE 3.15 mg/mL | Ophthalmic | Bausch & Lomb Incorporated × 2 listings | NDA | View NDC → |
| 0.2675; 3.15 mg/mL; mg/mL | Ophthalmic | Bausch & Lomb Incorporated | NDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.2675 mg/mL; PHENIRAMINE MALEATE 3.15 mg/mL | Ophthalmic | Cvs Pharmacy | NDA | View NDC → |
| 0.2675; 3.15 mg/mL; mg/mL | Ophthalmic | Cvs Pharmacy | NDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.2675 mg/mL; PHENIRAMINE MALEATE 3.15 mg/mL | Ophthalmic | Dolgencorp, Llc | NDA | View NDC → |
| 0.25; 3 mg/mL; mg/mL | Ophthalmic | Johnson & Johnson Consumer Inc. × 2 listings | NDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.25 mg/mL; PHENIRAMINE MALEATE 3 mg/mL | Ophthalmic | Kenvue Brands LLC | NDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.2675 mg/mL; PHENIRAMINE MALEATE 3.15 mg/mL | Ophthalmic | Rite Aid Corporation | NDA | View NDC → |
| 0.2675; 3.15 mg/mL; mg/mL | Ophthalmic | Rite Aid Corporation | NDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.2675 mg/mL; PHENIRAMINE MALEATE 3.15 mg/mL | Ophthalmic | Target Corporation | NDA | View NDC → |
| 0.2675; 3.15 mg/mL; mg/mL | Ophthalmic | Target Corporation × 2 listings | NDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.2675 mg/mL; PHENIRAMINE MALEATE 3.15 mg/mL | Ophthalmic | Wal-Mart Stores Inc | NDA | View NDC → |
| NAPHAZOLINE HYDROCHLORIDE 0.2675 mg/mL; PHENIRAMINE MALEATE 3.15 mg/mL | Ophthalmic | Walgreen Company | NDA | View NDC → |
| 0.2675; 3.15 mg/mL; mg/mL | Ophthalmic | Walgreen Company × 2 listings | NDA | View NDC → |
Showing 24 of 24 products — FDA National Drug Code Directory. See every product, package size and price: browse all 24 Naphazoline / Pheniramine NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Naphazoline / Pheniramine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Naphazoline / Pheniramine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Naphazoline / Pheniramine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one exact multiple-ingredient concept (MIN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). A product with a different ingredient combination belongs on a different page.
RxCUI 597159 1 dose form · 2 strengths
-
Dose form (SCDF) Ophthalmic Solution RxCUI 372997In current FDA listingsClinical drug / strength (SCD) naphazoline hydrochloride 0.25 MG/ML / pheniramine maleate 3 MG/MLRxCUI 1043658naphazoline hydrochloride 0.27 MG/ML / pheniramine maleate 3.15 MG/MLRxCUI 1043704
Look up RxCUI 597159 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Naphazoline / Pheniramine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Naphazoline / Pheniramine belongs to the Sympathomimetics, plain class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 12 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Alcon Laboratories, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.